An Hepatitis E vaccine has been recently commercially developed and licensed in China. The vaccine contains a recombinant viral capsid protein. The available data for this vaccine relate to pre-exposure protection after administration of three doses over a 6-month period, and to a limited extent following that of the first two doses. The vaccine appears to be effective for at least 2 years; future follow-up studies should provide data on whether the vaccine provides longer-term protection. Limited data on safety during pregnancy are available .